growing a layer of keratinocytes over said dermal fibroblasts upon said upper side of said substratum to form a composite skin graft material, said keratinocytes being harvested from a target donor patient.

2. The method according to claim 1 wherein said dermal fibroblasts are allogenic to the keratinocytes.

3. The method according to claim 1 wherein said dermal fibroblasts are autologous to the keratinocytes.

4. A method for cultivating graftable skin comprising:

growing a first layer of dermal fibroblasts upon a basal side of a biosynthetic substratum of an esterified hyaluronic acid;

growing a second layer of dermal fibroblasts upon an upper side of said biosynthetic substratum; and

after said second dermal fibroblast layer begins to proliferate, growing a layer of keratinocytes over said dermal fibroblasts upon said upper side of said substratum to form a composite skin material, said keratinocytes having been harvested from a target donor patient.

5. The method according to claim 4 wherein said dermal fibroblasts are allogenic to the keratinocytes.

6. The method according to claim 4 wherein said dermal fibroblasts are autologous to the keratinocytes.

7. A method for cultivating graftable skin comprising:

growing a layer of keratinocytes upon an upper side of a substratum of a biosynthetic substratum of an esterified hyaluronic acid to form a composite skin graft material, said keratinocytes having been harvested from a target donor patient.

8. A graftable skin material compromising a composite of:

a biosynthetic substratum of an esterified hyaluronic acid;

a layer of dermal fibroblasts upon an upper side of said biosynthetic substratum; and

a layer of keratinocytes over said dermal fibroblasts upon said upper side of said substratum, said keratinocytes having been harvested from a target donor patient.

9. The material according to claim 8 wherein said dermal fibroblasts are allogenic to the keratinocytes.

10. The material according to claim 8 wherein said dermal fibroblasts are autologous to the keratinocytes.

11. A graftable skin material comprising a composite of:

a biosynthetic substratum of an esterified hyaluronic acid;

a first layer of dermal fibroblasts upon a basal side of said biosynthetic substratum;

a second layer of dermal fibroblasts upon an upper side of said biosynthetic substratum; and

a layer of keratinocytes over said dermal fibroblasts upon said upper side of said substratum, said keratinocytes having been harvested from a target donor patient.

12. The material according to claim 11 wherein said dermal fibroblasts are allogenic to the keratinocytes.

13. The material according to claim 11 wherein said dermal fibroblasts are autologous to the keratinocytes.

14. A graftable skin material comprising:

a substratum of a biosynthetic substratum of an esterified hyaluronic acid; and

a layer of keratinocytes upon an upper side of said substratum, said keratinocytes having been harvested from a target donor patient.

15. A method for grafting a graftable skin material comprising the steps of:

applying an artificial skin substrate upon a wound bed of a recipient patient; said artificial skin substrate comprising a layer of collagen-glycoaminoglycan on a basal side to be juxtaposed to said wound bed and a covering membrane of silicone on an opposing upper side;

allowing a vascularized wound bed to form under said collagen-glycoaminoglycan; thereupon

removing said silicone membrane; and

applying a basal side of a sheet of cultivated skin material over said collagen-glycoaminoglycan, said cultivated skin material comprising a layer of keratinocytes upon an upper side of a substratum, said keratinocytes being harvested from a target donor patient.

16. The method according to claim 15 wherein said cultivated skin material further comprises a layer of dermal fibroblasts upon an upper side of a biosynthetic substratum and wherein said layer of keratinocytes is over said dermal fibroblasts.

REMARKS

Claims 1-17 are pending in the present application. The Examiner rejects all of the pending claims.

Rejection under 35 U.S.C. 112

Claims 1-14

The Examiner rejects claims 1-14 under 35 U.S.C. 112, second paragraph, as unclear. Independent claims 1, 4, 7, 8, 11 and 14 recite the phrase: "derivative of benzyl esterified hyaluronic acid." The Examiner maintains that the claims are indefinite because the term "derivative" only denotes a source or starting material and does not clearly denote the end product to be utilized in the claim. Claims 2, 3, 5, 9, 10, 12 and 13 depend from the independent claims 1, 4, 7,